A Strategy for the Lung Cancer Treatment in Elderly Patients

DOI Web Site 23 References
  • Ichikawa Yasuko
    Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine
  • Ota Shuji
    Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine
  • Eguchi Kenji
    Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine

Bibliographic Information

Other Title
  • 高齢者に対する放射線・化学療法の考え方—呼吸器 (肺癌) —
  • 高齢者に対する放射線・化学療法の考え方 : 呼吸器(肺癌)
  • コウレイシャ ニ タイスル ホウシャセン ・ カガク リョウホウ ノ カンガエカタ : コキュウキ(ハイガン)

Search this article

Abstract

As the aging society progresses, today more than half of Japanese patients with lung cancer are age 75 years or over. Most elderly patients demonstrate a decline organ function with aging. Elderly people show variable comorbidities, and careful planning is necessary to predict the effect and toxicity of treatment. Large-scale clinical testing to establish a conventional standard therapy was prepared for ages from 20 to 74 years old with selective conditions ; it was not directly be applicable to elderly people. Results of clinical trials on elderly people have been accumulated progressively in recent years. Personalized medicine will become a major paradigm in the care and treatment of lung cancer in elderly patients.

Journal

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top